



Efflux Pumps In Antimicrobial Resistance: Mechanism, Regulation And Therapeutic Implications

Abhishek Ghoshal¹, Joydev Mallick², Suranjana Sarkar³, Semanti Ghosh⁴, Bidisha Ghosh⁵, Subhasis Sarkar^{6*}

^{1,2,3,4}Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrakpore, Kolkata- 700121

^{5,6*}Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrakpore, Kolkata- 700121

***Corresponding Author:** Subhasis Sarkar

***E-mail:** subhasiss@svu.ac.in

Article History	Abstract
Received: 30/09/2023 Revised: 15/10/2023 Accepted: 30/10/2023	Efflux pumps play a crucial role in antimicrobial resistance, enabling bacteria to extrude a wide range of antibiotics and other antimicrobial compounds, thereby reducing their intracellular concentration and rendering them ineffective. Understanding the mechanisms underlying efflux pump-mediated resistance is essential for the development of effective strategies to combat this growing threat. This review paper provides an overview of the various efflux pump systems, their regulation mechanisms, and their impact on antimicrobial resistance. Additionally, we discuss the potential therapeutic interventions that target efflux pumps to restore the efficacy of antimicrobial agents.
CC License CC-BY-NC-SA 4.0	Key Words: Antibiotics, Antimicrobial resistance, Efflux pumps

1.0. Global Antimicrobial Resistance Crisis

The global antimicrobial resistance (AMR) crisis refers to the growing and alarming phenomenon where bacteria, viruses, parasites, and fungi are becoming resistant to the drugs (antibiotics, antivirals, antifungals, and antiparasitics) that were once effective in treating infections (Founou et al. 2017). This resistance reduces the efficacy of these drugs, making it increasingly challenging to treat common infections, increasing healthcare costs, and leading to higher mortality rates. The effectiveness of antibiotics, which have revolutionized medicine and saved millions of lives, is in jeopardy due to the increasing rise of resistant bacteria throughout the world. Several decades after the first patients received antibiotic treatment, bacterial infections are once more a danger. The overuse and abuse of these drugs, as well as the pharmaceutical industry's lack of new drug research as a result of diminished economic incentives and onerous regulatory constraints, have all been linked to the challenge of antibiotic resistance (Ventola C. L., 2015).

2.0. Efflux Pumps in Antibiotic Resistance

Efflux pumps play a significant role in antibiotic resistance, contributing to the persistence of resistant bacteria. These are specialized transport proteins found in the cell membranes of bacteria that actively pump out antibiotics and other toxic substances from the bacterial cell. Efflux pumps work by expelling antibiotics out

of bacterial cells before they can reach their targets, such as enzymes or structures essential for bacterial survival (Soto S. M., 2013). This reduces the effectiveness of antibiotics. Many efflux pumps can pump out multiple classes of antibiotics, making bacteria resistant to a wide range of drugs simultaneously (Li X. Z., & Nikaido H., 2009). Bacteria can have intrinsic (naturally occurring) efflux pumps that provide baseline resistance, and they can also acquire additional efflux pumps through genetic mutations or horizontal gene transfer, further enhancing resistance. Efflux pumps contribute to bacterial persistence, allowing them to survive in the presence of antibiotics, even at sub-lethal concentrations. This can lead to recurrent infections and treatment failure. The presence of efflux pumps in resistant bacteria complicates the treatment of infections, as they reduce the effectiveness of antibiotics. This necessitates the development of new strategies and drugs to counteract efflux pump-mediated resistance. Efflux pumps are just one facet of the complex problem of antimicrobial resistance, but understanding their role is crucial for effectively developing strategies to combat this global health threat. Efforts to combat AMR involve a multifaceted approach, including responsible antibiotic use, surveillance, infection prevention, and the development of new antibiotics and therapies.

Efflux pumps are critical components of bacterial defense mechanisms against antimicrobial agents. These pumps actively remove toxic substances, including antibiotics, from within the bacterial cell, thereby conferring resistance. Three major classes of efflux pumps are widely recognized: ATP-Binding Cassette (ABC) transporters, Major Facilitator Superfamily (MFS) transporters, and Resistance-Nodulation-Division (RND) transporters.

3.0. ABC Transporters:

ABC transporters utilize energy derived from ATP hydrolysis to pump substances out of the bacterial cell (Wilkens S., 2015). They consist of two membrane-spanning domains and two cytoplasmic ATP-binding domains (Fig. 1). ABC transporters have a broad substrate range, pumping out various molecules, including antibiotics, toxins, and metabolic byproducts. Prominent examples of ABC transporters involved in antibiotic resistance include the NorA pump in *Staphylococcus aureus* and the AcrB pump in *Escherichia coli* (Sharma et al. 2019).

4.0. MFS Transporters:

MFS transporters are passive transporters that rely on the proton motive force to move substrates across the bacterial membrane. They function as uniporters, symporters, or antiporters. MFS transporters (Fig. 1) are known for their role in multidrug resistance and can efflux a wide array of substrates including antibiotics, sugars, and organic acids (Dos Santos et al., 2014). The Tet family of efflux pumps, such as TetA in *Escherichia coli*, is a well-known example of MFS transporters involved in antibiotic resistance.




Fig-1; ABC and MFS Transporters: A reason for Antifungal drug resistance

5.0. RND Transporters (Resistance-Nodulation-Division):

RND transporters are complex tripartite efflux systems consisting of an inner membrane transporter (e.g., AcrB), a periplasmic adapter protein e.g., AcrA, and an outer membrane channel protein (e.g., TolC) (Nikaido H., 2018). Together, they form a continuous channel for substrate efflux. RND transporters are a major

contributor to antibiotic resistance in Gram-negative bacteria. They are capable of effluxing a wide range of antibiotics, detergents, and toxic compounds. The AcrAB-TolC efflux system in *Escherichia coli* and the MexAB-OprM system in *Pseudomonas aeruginosa* are notable examples of RND transporters associated with antibiotic resistance (Klenotic P. A., 2021). Efflux pumps from these three major classes are often expressed in bacterial cells as a response to antibiotic exposure or other stressors. They confer resistance by preventing the accumulation of antibiotics at lethal intracellular concentrations. This resistance mechanism is a significant challenge in the treatment of bacterial infections, as it reduces the effectiveness of antibiotics and contributes to the persistence of drug-resistant bacteria.

Efforts to combat antibiotic resistance include the development of efflux pump inhibitors and the discovery of novel antimicrobial agents that can bypass or overcome efflux pump-mediated resistance. Understanding the different classes of efflux pumps and their mechanisms is crucial for devising strategies to counteract bacterial resistance and preserve the efficacy of antibiotics. Efflux pump-mediated resistance in bacteria involves several mechanisms that allow the pump to recognize, bind to, and expel specific substrates, including antibiotics and other toxic compounds.

6.0. Mechanisms of Efflux Pump-Mediated Resistance

6.1. Substrate Recognition and Binding

Efflux pumps recognize and bind to specific substrates through various mechanisms; Efflux pumps are selective in the substrates they recognize. Each pump is designed to recognize and bind to certain types of molecules, such as antibiotics, toxins, or detergents. Efflux pumps have binding sites or pockets that accommodate their substrates. These binding sites are often specific to the chemical structure of the substrate molecules. Bacteria can adapt over time to recognize and pump out a broader range of substrates (Sharma et al., 2010). Mutations in the genes encoding the efflux pump proteins can lead to altered substrate specificity.

6.2. Energy-Driven Efflux Mechanisms

Efflux pumps require energy to actively transport substrates out of the cell. This energy-driven mechanism involves several components: Most efflux pumps use energy derived from the hydrolysis of ATP (adenosine triphosphate) or the proton motive force (PMF) generated by the electron transport chain. Efflux pumps consist of multiple proteins, including transporter proteins (membrane proteins) and accessory proteins. These proteins work together to facilitate substrate transport (Levy S.B., 2002). Energy is used to pump substrates against their concentration gradient, meaning they are expelled from the cell even when their extracellular concentration is lower than intracellular.

6.3. Cross-Resistance and Co-Regulation with Other Resistance Mechanisms

Efflux pumps can be involved in cross-resistance, where resistance to one type of substrate confers resistance to multiple related compounds (Sharma et al., 2010). Additionally, they can be co-regulated with other resistance mechanisms: Efflux pumps that confer resistance to one class of antibiotics or toxic compounds may also provide resistance to structurally related compounds. For example, a pump conferring resistance to tetracycline antibiotics may also expel other tetracycline-like molecules. Efflux pump expression can be regulated alongside other resistance mechanisms. For instance, bacteria may upregulate efflux pump genes in response to the presence of antibiotics, but they may also have mechanisms like beta-lactamase production or target site modifications operating simultaneously. Bacteria can overexpress efflux pump genes as a response to antibiotic exposure. This overexpression can lead to higher efflux rates and increased resistance. Efflux pump-mediated resistance involves substrate recognition and binding, energy-driven mechanisms for substrate expulsion, and can lead to cross-resistance to related compounds. Efflux pumps may also be co-regulated with other resistance mechanisms, contributing to bacteria's overall antibiotic resistance phenotype. Understanding these mechanisms is crucial for developing strategies to combat antibiotic resistance.

7.0. Regulation of Efflux Pump Expression:

The expression of efflux pumps in bacteria is tightly regulated, and it can be influenced by various factors, including transcriptional regulators and environmental conditions.

7.1. Transcriptional Regulators and Regulatory Networks:

Efflux pump expression is often controlled by specific transcriptional regulators and can be part of broader regulatory networks: Bacteria have specific transcription factors that bind to promoter regions of efflux pump

genes. These factors can either activate (inducers) or repress (repressors) gene expression based on various signals (Alav et al. 2021). Efflux pump genes can be induced or repressed in response to different stimuli. For example, exposure to antibiotics or toxic compounds can trigger the activation of specific transcription factors, leading to increased efflux pump expression. Bacteria often possess multiple efflux pumps, and their expression can be regulated independently or coordinately. Some regulatory systems control multiple pumps simultaneously. In addition to specific regulators for individual efflux pumps, bacteria may have global regulatory systems that control various aspects of antibiotic resistance, including efflux pump expression. Examples include the MarA/SoxS/Rob and the TetR family of regulators.

7.2. Environmental Factors Influencing Efflux Pump Expression:

The expression of efflux pumps can be influenced by various environmental factors: Exposure to antibiotics, disinfectants, and toxins can induce the expression of efflux pump genes. Bacteria can perceive these compounds as stressors and respond by upregulating efflux pumps to expel the toxic substances. The availability of nutrients can impact efflux pump expression. In some cases, nutrient limitation can lead to increased efflux pump expression as bacteria adapt to stressful conditions. Environmental conditions such as pH and temperature can affect efflux pump expression. Changes in pH can alter the proton motive force (PMF), which may impact the energy source for efflux pumps. Oxygen availability can also influence efflux pump regulation. Anaerobic conditions, where oxygen is scarce, can lead to altered regulation of efflux pumps (Ayala et al., 2022). Bacteria in biofilms, which are microbial communities attached to surfaces, may exhibit different efflux pump expression patterns compared to planktonic (free-floating) bacteria. Biofilm-associated bacteria can be more resistant to antibiotics due to altered gene expression. Some bacteria use quorum sensing systems to coordinate gene expression in response to cell density. Efflux pump expression may be part of these quorum-sensing networks. Bacterial stress response systems, such as the SOS response, can trigger changes in efflux pump expression in the presence of DNA-damaging agents. Understanding the regulation of efflux pump expression is crucial for developing strategies to combat antibiotic resistance. By targeting the regulatory networks and environmental cues that influence efflux pump expression, researchers and clinicians can develop more effective approaches to tackle multidrug-resistant bacteria.

8.0. Contribution of Efflux Pumps to Antimicrobial Resistance:

8.1. Efflux Pumps and Multidrug Resistance:

Efflux pumps play a crucial role in multidrug resistance (MDR) by actively pumping out multiple classes of antimicrobial agents (Soto S.M., 2013). Hepe a wide range of compounds, including antibiotics, antivirals, antifungals, and toxins, simultaneously makes bacteria resistant to multiple drugs. Bacteria that overexpress efflux pumps can effectively reduce the intracellular concentration of antimicrobial agents, rendering them less effective against the pathogen. Efflux pump-mediated MDR complicates the treatment of bacterial infections, as it limits the available therapeutic options and can lead to treatment failures.

8.2. Efflux Pumps in Specific Bacterial Species or Genera:

Efflux pumps are found in various bacterial species and genera, contributing to resistance in different contexts. *Pseudomonas aeruginosa* possesses efflux pumps like MexAB-OprM and MexXY that are associated (Fig. 2) with resistance to a broad range of antibiotics, including beta-lactams and fluoroquinolones. These pumps are a major factor in this pathogen's intrinsic and acquired resistance. In *Staphylococcus aureus*, the NorA efflux pump is known for its role in expelling fluoroquinolone antibiotics, contributing to the development of methicillin-resistant *S. aureus* (MRSA) strains. *E. coli* harbors the AcrAB-TolC efflux system (Yu, X. H., et al., 2022), which plays a significant role in resistance to multiple antibiotics, including beta-lactams, tetracyclines, and fluoroquinolones. This system is responsible for MDR in many clinical isolates. Efflux pumps like Rv1258c in *Mycobacterium tuberculosis* can expel anti-tuberculosis drugs, contributing to the persistence of the bacterium in the host and making tuberculosis treatment more challenging. The MtrCDE efflux pump in *Neisseria gonorrhoeae* is associated with resistance to antibiotics used to treat gonorrhea, such as fluoroquinolones (Handing, et al., 2018). Its presence complicates the management of this sexually transmitted infection. Efflux pumps can vary in their substrate specificity and expression levels among different bacterial species, making them significant factors in the antibiotic resistance profiles of these pathogens. Understanding the role of efflux pumps in specific bacteria is essential for tailoring treatment strategies and combating antimicrobial resistance effectively.




Fig-2: Schematic illustration of the main efflux pump MexAB-OprM in *Pseudomonas aeruginosa* as examples for the Resistance-Nodulation-Division (RND) family showing that it is energy dependent on hydrogen protons

9.0. Therapeutic Strategies in Efflux Pump Inhibition

Efflux pump inhibitors (EPIs) are compounds designed to block or inhibit the activity of bacterial efflux pumps. These inhibitors can be used as adjuncts to conventional antibiotics to enhance their effectiveness. EPIs are often used in combination with antibiotics to combat antibiotic-resistant bacteria. By inhibiting efflux pumps, EPIs can prevent the expulsion of antibiotics from bacterial cells, allowing higher intracellular antibiotic concentrations and improved antimicrobial activity. When used alongside antibiotics, EPIs can help restore the potency of antibiotics that have become less effective due to efflux pump-mediated resistance. Some EPIs have shown effectiveness against a variety of efflux pumps in different bacterial species, making them potential tools for addressing multidrug resistance.

10.0. Challenges and Future Prospects of EPI Development:

Developing effective EPIs presents challenges but holds promise for combating antimicrobial resistance. Designing EPIs that selectively target efflux pumps without affecting host cells or beneficial microbiota is challenging but essential for safety and effectiveness. Bacteria can develop resistance to EPIs, which can limit their long-term utility. Combining multiple EPIs or using them in combination with antibiotics can mitigate this issue. The development of EPIs and their approval for clinical use require rigorous testing in clinical trials to assess safety, efficacy, and potential drug interactions. EPIs are part of a multifaceted approach to combat antimicrobial resistance. Future research may focus on identifying and optimizing EPIs, exploring their synergistic effects with new antibiotics, and developing personalized treatment strategies based on bacterial resistance profiles. In addition to EPIs, other approaches, such as the development of new antibiotics with reduced susceptibility to efflux pumps or the use of phage therapy, are being explored to address bacterial resistance. Efflux pump inhibition represents a promising strategy to overcome antimicrobial resistance, especially in bacteria where efflux pumps are a significant factor. However, the development of safe and effective EPIs requires ongoing research and collaboration among scientists, pharmaceutical companies, and regulatory agencies to address the challenges and bring these adjunct therapies to the clinic.

Efflux pumps play a crucial role in the resistance of many microorganisms, including bacteria and fungi, to various antimicrobial agents. These pumps are membrane proteins that actively transport drugs and toxins out of cells, reducing the intracellular concentration of the compound and rendering the treatment less effective. Understanding the impact of efflux pumps on treatment outcomes and developing combination therapies that target these pumps are important in the fight against antimicrobial resistance.

11.0. Clinical Implications

Efflux pumps can significantly reduce the intracellular concentration of antibiotics, antifungals, and other antimicrobial agents. As a result, infections caused by microorganisms with active efflux pumps are often more difficult to treat and may require higher doses or longer treatment durations. In some cases, treatment failure can occur when the causative microorganism possesses efflux pumps that actively pump out the prescribed medications. This can lead to prolonged infections, increased healthcare costs, and potential complications.

Efflux pumps are often associated with multidrug resistance, where microorganisms become resistant to multiple classes of antimicrobial agents. This poses a significant challenge in clinical practice, as fewer treatment options are available for these infections.

12.0. Conclusion

Efflux pumps are pivotal contributors to antimicrobial resistance, allowing bacteria to expel a diverse array of antibiotics and antimicrobial substances, diminishing their intracellular concentration and thwarting their effectiveness. A comprehensive understanding of the mechanisms orchestrating efflux pump-mediated resistance is imperative for devising efficacious strategies against this escalating challenge. This review has provided an extensive overview of different efflux pump systems, elucidating their intricate regulatory mechanisms and their profound role in fuelling antimicrobial resistance. The insights gathered underscore the urgency of addressing efflux pump-mediated resistance in the fight against infectious diseases.

Furthermore, we have explored potential therapeutic interventions aimed at countering efflux pumps, with the aim of restoring the potency of antimicrobial agents. These strategies, such as combination therapies with efflux pump inhibitors and the pursuit of novel inhibitors, hold promise in mitigating resistance and improving treatment outcomes.

Conflict of Interest

Authors do not have any competing interest.

Acknowledgement

Authors will remain indebted to the Department of Microbiology, Swami Vivekananda University for providing necessary supports in completion of this project.

References:

1. Alav, I., Kobylka, J., Kuth, M. S., Pos, K. M., Picard, M., Blair, J. M. A., & Bavro, V. N. (2021). Structure, Assembly, and Function of Tripartite Efflux and Type 1 Secretion Systems in Gram-Negative Bacteria. *Chemical Reviews*, 121(9), 5479–5596. <https://doi.org/10.1021/acs.chemrev.1c00055>
2. Ayala, J. C., Balthazar, J. T., & Shafer, W. M. (2022). Transcriptional regulation of the *mtrCDE* efflux pump operon: importance for *Neisseria gonorrhoeae* antimicrobial resistance. *Microbiology (Reading, England)*, 168(8), 001231. <https://doi.org/10.1099/mic.0.001231>
3. Founou, R. C., Founou, L. L., & Essack, S. Y. (2017). Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis. *PloS one*, 12(12), e0189621. <https://doi.org/10.1371/journal.pone.0189621>
4. Klenotic, P. A., Moseng, M. A., Morgan, C. E., & Yu, E. W. (2021). Structural and Functional Diversity of Resistance-Nodulation-Cell Division Transporters. *Chemical reviews*, 121(9), 5378–5416. <https://doi.org/10.1021/acs.chemrev.0c00621>
5. Levy, S.B. Active efflux, a common mechanism for biocide and antibiotic resistance. *J Appl Microbiol.* 2002;92 Suppl:65S-71S.
6. Li, X. Z., & Nikaido, H. (2009). Efflux-mediated drug resistance in bacteria: an update. *Drugs*, 69(12), 1555–1623. <https://doi.org/10.2165/11317030-000000000-00000>
7. Nikaido H. (2018). RND transporters in the living world. *Research in microbiology*, 169(7-8), 363–371. <https://doi.org/10.1016/j.resmic.2018.03.001>
8. Sharma, A., Gupta, V. K., & Pathania, R. (2019). Efflux pump inhibitors for bacterial pathogens: From bench to bedside. *The Indian journal of medical research*, 149(2), 129–145. https://doi.org/10.4103/ijmr.IJMR_2079_17
9. Soto S. M. (2013). Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm. *Virulence*, 4(3), 223–229. <https://doi.org/10.4161/viru.23724>
10. Ventola C. L. (2015). The antibiotic resistance crisis: part 1: causes and threats. *P & T : a peer-reviewed journal for formulary management*, 40(4), 277–283.
11. Wilkens S. (2015). Structure and mechanism of ABC transporters. *F1000prime reports*, 7, 14. <https://doi.org/10.12703/P7-14>